New map of brain immune cells: what it means for MS

Credibility

Interest

Share:2 min read

Key Takeaway

This study shows that CSF1R-positive microglia (a type of brain immune cell) rise mainly in white matter in progressive MS, while other brain diseases show increases in specific brain regions.

What They Found

Researchers counted CSF1R-positive microglia (microglia are the brain's immune cells; CSF1R is a protein on their surface) across many brain regions in several diseases. In Alzheimer’s and other neurodegenerative diseases, some parts of the cortex had more CSF1R-positive microglia, but the changes were small and varied by region, like hotspots rather than a whole-brain rise. In progressive MS, the number of CSF1R-positive microglia in the gray matter (the brain’s outer layer where thinking happens) was similar to controls, but white matter (the brain’s wiring) showed an increase, especially in later-stage MS. The team also compared CSF1R-positive microglia to measures of presynaptic markers (SV2A and synaptophysin, which are proteins found where nerve cells connect) and found that regions with more CSF1R-positive microglia often also had signs of preserved synapses, not necessarily more damage. Overall, the study provides a detailed map of where CSF1R-positive microglia are increased across diseases, which can help interpret brain scans that target CSF1R.

Who Should Care and Why

MS patients and caregivers should care because the study suggests that immune changes tied to CSF1R are more pronounced in the white matter in progressive MS, and white matter damage often relates to mobility and coordination problems. Clinicians and researchers should care because this map helps interpret future brain scans that look for CSF1R, making it clearer whether a bright area on a scan means immune activity in gray or white matter. Caregivers might use this to understand why symptoms can change as MS progresses, since white matter issues affect signals traveling between brain areas like a damaged cable slowing internet. People considering or on treatments that target microglia or CSF1R will find this relevant, because it suggests where such treatments might act in the brain. Finally, patients interested in future imaging tests (PET scans) should know that location matters: a scan showing CSF1R may mean different things if it lights up white matter versus cortex.

Important Considerations

The study looked at tissue after death, so it shows where cells were at that time but not how they changed over time in people. The links between CSF1R-positive microglia and preserved synapses are exploratory and do not prove one causes the other. Findings may not apply to every person with MS because the sample sizes and brain regions studied are limited.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Progression MS Diagnostics

Article Topics:

Alzheimer’s DiseaseCSF1RFrontotemporal DementiaMicrogliaMultiple SclerosisSynapse/synaptic

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News